Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Epcoritamab Monotherapy Induces Complete Responses in R/R CLL

December 8th 2024

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

TRANSCEND CLL 004 Analysis Proposes Meaningful Change Thresholds for PRO Measures in R/R CLL

December 4th 2024

Meaningful thresholds for interpreting changes in 3 EORTC QLQ-CLL17 domain scores have been identified in a PRO analysis of the TRANSCEND CLL 004 trial.

OncLive’s November Roundup of Key FDA Approvals in Oncology

December 3rd 2024

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL

November 21st 2024

NX-5948 has received PRIME designation from the EMA for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL

November 20th 2024

An NDA for lisaftoclax in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma has been accepted for review.

FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL

November 20th 2024

The FDA has approved revised drug labeling for fludarabine phosphate under Project Renewal.

Dr Allan on Efforts to Clarify the Optimal Treatment Sequence in CLL

November 20th 2024

John N. Allan, MD, discusses ongoing efforts to address areas of uncertainty regarding the optimal sequencing strategy in CLL.

Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL

November 19th 2024

Kathleen A. Dorritie, MD, discusses 5-year of follow-up data from the CAPTIVATE trial in chronic lymphocytic leukemia and/or small lymphocytic lymphoma.

Dr DeAngelo on Non-Chemotherapy Treatment Options in CLL

November 15th 2024

Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.

Piecing Together the Proper BTK Usage in CLL

November 13th 2024

Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.

First-Line Zanubrutinib Prolongs PFS in Real-World Study of Chinese Patients With CLL/SLL

November 13th 2024

First-line zanubrutinib generated a longer PFS in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma vs relapsed/refractory disease.

The OncFive: Top Oncology Articles for the Week of 11/3

November 9th 2024

Obe-cel wins FDA approval in relapsed/refractory B-cell ALL, FDA approval is sought for sunvozertinib in EGFR exon 20–positive NSCLC, and more.

Dr Fisher on Mechanisms of Resistance to Pirtobrutinib in CLL

November 6th 2024

David C. Fisher, MD, discusses pirtobrutinib resistance mechanisms that may develop during therapy in patients with CLL

Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024

November 6th 2024

Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL

November 4th 2024

Treatment with the third-generation anti-CD19 CAR T-cell therapy HD-CAR-1 is feasible and safe in heavily pretreated chronic lymphocytic leukemia.

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens

October 29th 2024

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

Dr Fisher on Mechanisms of Resistance with Covalent BTK Inhibitors in CLL

October 23rd 2024

David C. Fisher, MD, discusses resistance mechanisms observed among patients with CLL who were previously treated with covalent BTK inhibitors.

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

October 21st 2024

David C. Fisher, MD, discusses the evolving role of BTK inhibitors in the CLL treatment paradigm.

Venetoclax/Rituximab Retreatment Produces Durable Responses in CLL

October 16th 2024

Retreatment with venetoclax plus rituximab generated responses in patients with CLL who had responded to and progressed after initial venetoclax treatment.